KDC/ONE

Key Takeaways

• Potential fit: custom products that require formulation, packaging and production decisions to be coordinated.
• Main advantage: a broad international network spanning R&D, design, packaging and manufacturing across several product categories.
• Main qualification point: capabilities must be verified at the facility level rather than assumed from the company-wide network.
• Main commercial unknowns: MOQ, development timing, formula ownership, exclusivity and site-specific certifications must be established during the RFQ process.

The Shortlist Decision in One View

Evaluate KDC/ONE at Two Different Levels

A supplier can appear suitable at the corporate level and still be wrong for a particular SKU. Separating platform fit from project fit prevents a large network from being mistaken for a universal manufacturing solution.

Company Scale Without Confusing Size With Suitability

These figures indicate a substantial development and production platform. They do not reveal whether a particular line has available capacity, whether a specific formula can be transferred between sites or whether the commercial minimum is suitable for a new launch.

Where Integrated Development Can Reduce Project Risk

Formula, packaging and manufacturing decisions are interdependent. A formula may be stable in a laboratory sample but unsuitable for the intended pump, filling temperature, mixing process or production line. KDC/ONE’s integrated model is most valuable when these dependencies are addressed before specifications are locked.

Beauty and Personal Care Product Scope

KDC/ONE covers a broad range of product formats, which may suit brands developing a collection across multiple categories. Availability still needs to be mapped to the proposed manufacturing site.

Home Care and Other Regulated Categories

KDC/ONE’s home care portfolio includes air care, specialty fabric care, surface care and pest-control formats. Its broader operating scope also includes pharmaceutical, natural health, industrial and medical categories.

This breadth should not be interpreted as one common regulatory or manufacturing pathway. An air-care device, surface cleaner, cosmetic serum, sunscreen and medical product can involve different authorities, testing programs, claims restrictions and production controls.

A Global Network Creates Options, Not Automatic Portability

A broad network can offer more choices for development, sourcing and production geography. It can also introduce handoffs between teams, facilities and legal entities. The brand should understand the route before comparing cost or timing.

1. Identify Where the Formula Will Be Developed

   The development laboratory may not be located at the eventual manufacturing plant. Confirm how the process will be transferred and revalidated.

2. Identify Where Components Will Be Sourced

   Packaging suppliers, decoration vendors and raw-material sources may affect minimums, currency exposure, freight and replacement lead times.

3. Identify Where Testing Will Be Conducted

   Clarify which facility or third party performs stability, compatibility, microbiological, safety and performance testing.

4. Identify Where Each SKU Will Be Manufactured

   A multi-category line may be split across facilities. Confirm who coordinates specifications, artwork, release timing and finished-goods consolidation.

What the 2026 AI Partnership Does—and Does Not—Establish

KDC/ONE announced a multi-year partnership with Potion AI in January 2026. The program is designed to support ingredient discovery, formula generation and regulatory-compliance screening within selected laboratories and innovation hubs.

The initial rollout covers selected North American laboratories, with further deployment planned after validation. Brands should therefore ask whether the team assigned to their project uses the platform and which parts of development it supports.

MOQ and Emerging-Brand Fit Require Separate Answers

KDC/ONE works with established and emerging brands. That statement does not mean every facility, formula or package is commercially suitable for a small opening order.

The business inquiry form allows estimated volumes from fewer than 10,000 units to more than 100,000 units per SKU. This shows that sub-10,000-unit projects can be submitted for review; it does not establish a published MOQ or guarantee acceptance.

Ask for all five minimums. A single “MOQ” number can hide the component or production commitment that creates the larger inventory exposure.

For a U.S. Launch, Regulatory Strategy Starts Before Formulation

Product classification, intended claims and responsible-party roles should be defined before the formula and package are approved. Changing them late can require different ingredients, tests, labels, facilities or regulatory pathways.

1. Determine Whether the Product Is a Cosmetic, Drug or Both

A product intended only to cleanse, beautify or alter appearance is generally regulated as a cosmetic. Claims to treat or prevent disease, or to affect the structure or function of the body, can make the product a drug.

Examples of cosmetic-and-drug combinations include antidandruff shampoos, antiperspirant deodorants, sunscreens and moisturizers or makeup carrying sun-protection claims. The term “cosmeceutical” has no legal meaning under the FD&C Act.

2. Do Not Treat Registration as FDA Approval

Cosmetic products and cosmetic ingredients generally do not require FDA premarket approval, except for color additives. They must still be safe under labeled or customary conditions of use, properly labeled and compliant with the laws against adulteration and misbranding.

A statement such as “FDA registered” must not be used to imply that FDA approved the cosmetic or confirmed its performance.

3. Assign MoCRA Responsibilities by Role

The responsible person is the manufacturer, packer or distributor whose name appears on the label. The brand should not assume that hiring a contract manufacturer automatically transfers responsible-person obligations.

4. Review the Label and Advertising as One Claims System

Product classification can be influenced by intended-use claims made on packaging, websites, social media and other promotional materials. A compliant ingredient list does not make an unsupported performance or health claim acceptable.

Objective advertising claims must be truthful, not misleading and adequately substantiated. Health-related claims generally require competent and reliable scientific evidence, and implied claims are evaluated as well as explicit statements.

Build the Contract Around the Product Lifecycle

The development quotation explains how the product reaches launch. The quality and supply agreements determine what happens after launch when a raw material changes, a component fails, demand exceeds the forecast or a complaint requires investigation.

What to Send in the First RFQ

A useful RFQ gives KDC/ONE enough information to select the right team and identify feasibility issues before extensive sampling or pricing work begins.

• Target consumer, market, retail channel and intended launch countries
• Finished-product category, format and number of SKUs
• Formula status: existing, stock, semi-custom or fully custom
• Target texture, sensory profile, performance and claims
• Required ingredients, prohibited ingredients and retailer standards
• Preferred packaging format, materials and decoration
• Estimated initial and annual volume per SKU
• Target launch date and internal approval milestones
• Required tests, certifications and regulatory documentation
• Preferred production region and supply-continuity requirements
• Formula ownership, confidentiality and exclusivity expectations

KDC/ONE’s inquiry form asks for the required capability, production country, number of SKUs, finished-product type, formula status, packaging type, launch timing and approximate units per SKU. Preparing these details first should make the initial qualification discussion more productive.

Questions That Should Be Answered Before Development Begins

1. Which KDC/ONE entity and facility will handle each stage?

   Identify the development laboratory, test location, packaging team, manufacturing plant and contracting entity.

2. What is included in the quoted development fee?

   Confirm the number of samples, revisions, tests, artwork reviews, documentation packages and project-management services.

3. What event starts the production lead time?

   Lead time may begin after formula approval, component arrival, artwork approval or purchase-order acceptance. Define the starting point.

4. Which changes require reapproval or retesting?

   Raw-material substitutions, supplier changes, package changes and production transfers may affect specifications or previous test results.

5. Who can use or transfer the final formula?

   Separate ownership of the formula from the right to manufacture it elsewhere and from ownership of background intellectual property.

6. What happens if demand is materially above or below forecast?

   Agree on capacity allocation, purchase commitments, excess components, obsolete inventory and reorder timing.

Frequently Asked Questions About KDC/ONE

KDC/ONE Company Information